There were no significant differences in patient clinico-pathological features between 1 response classes before treatment (Table 1) . However, PAM50 intrinsic molecular subtypes 2 were found to change during endocrine treatment (Fig. 1d ). These changes were consistent 3 with known associations with outcome, with all dormant tumours either remaining the same, 4 or switching to better prognosis luminal A or normal-like tumours. For resistant tumours, 5 however, 25% (5 out of 20) switched to a subtype of worse prognosis (Fig. 1d) . 6 As expected, Kaplan-Meier survival analysis demonstrated significantly worse outcomes for 7 resistant compared to dormant patients (log rank, p = 0.026, Fig. 1e ). Recurrence rates for 8 dormant and resistant patients were 21% (9/42) and 45% (9/20), respectively. Moreover, 9 resistant patients suffered significantly earlier recurrences compared to dormant patients (p = 1 0 0.05; range = 26-947 vs 136-2042 days; Fig. 1f ). in response to treatment for both dormant and acquired resistant samples (Fig. 2b) , although 2 1 long-term dormant samples were much more distinguishable from pre-treatment samples than 2 2 the long-term acquired resistant samples ( Fig. 2b ).
3
Correlations between tumours from different individuals (inter-patient) remained similar at 2 4 each time point and were not different between response classes (not shown). However, 2 5 correlations between matched sequential samples (intra-patient) revealed that pre-treatment 1 samples were significantly (p = 0.01) less similar to their long-term treated pairs (median = 2 0.89, range = 0.74-0.95) than their early-on treatment pairs (median = 0.91, range = 0.84-3 0.95) ( Fig. 2c ). However, when divided by dormancy status this finding was only significant 4 (p = 0.01) for dormant patients (Fig. 2c ), suggesting that dormant tumours continue to 5 diverge transcriptionally, whereas acquired resistant tumours do not consistently differ after 6 initial or extended treatment, as mirrored in the MDS representation ( Fig. 2b) . up-regulated) (Additional file 2: Table S1 ). These genes were significantly enriched (p < 1 1 0.01) for a total of 62 and 26 pathways, respectively (Additional file 2: Table S2 ), including 1 2 reductions in cell cycle, senescence, DNA methylation and an increase in extracellular matrix 1 3 (ECM) organization. These findings are consistent with previous studies of patient-matched 1 4 sequential endocrine treated samples [16] [17] [18] . Acquired resistant tumours displayed much 1 5 fewer consistently differentially expressed genes (238, 63 down-and 175 up-regulated) 1 6 between long-term treated and pre-treatment samples (Additional file 2: Table S3 ). Genes 1 7 that were up-regulated in resistant patients were enriched for several of the same pathways as down-regulated genes were much more variable (Additional file 2: Table S4 ; Fig. 3a-b ).
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Having determined that dormant and acquired resistant tumours have somewhat distinct 2 1 changes during treatment at the molecular level, the question remained as to whether these 2 2 changes tend to occur at earlier time points or were specific to long-term treatment. For 2 3 dormant tumours, differential expression begins early-on, but becomes more pronounced at 2 4 later timepoints ( Fig. 3a) . Down-regulated genes were most evident early-on treatment for 2 5 1 0 resistant patients, consistent with their initial response to treatment; whilst up-regulated genes 1 were most changed after long-term treatment, potentially suggesting that these genes may 2 mediate acquired resistance ( Fig. 3b ). We further examined whether differentially expressed 3 genes identified in each response class were shared ( Fig. 3c-d ). Both down-and up-regulated 4 genes identified in resistant tumours were significantly changed (p < 0.01) in dormant 5 patients ( Fig. 3d ). However, only up-regulated genes identified in dormant patients were 6 significantly up-regulated in resistant patients without any change in down-regulated genes 7 ( Fig. 3c ), implicating a partial lack of response to treatment at the molecular level in acquired 8 resistance patients.
9
A potential role of epigenetic regulation in acquired resistance 1 0
The above findings suggested that therapy-induced dynamic changes in genes and pathways file 2: Table S5 ; Fig. 4a ). These genes were significantly enriched in 27 pathways (p < 0.05), 1 7
including several epigenetics-related pathways, including "DNA methylation", "PRC2 1 8 methylates histones and DNA", "histone acetyl transferases (HATs) acetylate histones", 1 9
"epigenetic regulation of gene expression" as well as senescence and cell cycle (Additional 2 0 file 2: Table S6 ; Fig. 4b ). Examination of the expression of these genes alone, demonstrated 2 1 that they could partially separate dormant from majority of resistant tumours (Fig. 4c ).
2
Single-sample Gene Set Enrichment Analysis (ssGSEA) [30] was performed to quantitatively 2 3 score the activity of differentially expressed genes in every sample. The differentially up-2 4 1 1 regulated genes' score was significantly higher in acquired resistant compared to dormant 1 tumours under early-on (p < 0.05) as well as long-term (p < 0.001) treatment ( Fig. 4d ). with an initial decrease in ssGSEA scores mimicking the dormancy/responsive state was 1 2 followed by a later-on increase representing acquired resistance ( Fig. 5b ), further validating 1 3 our results and emphasizing the utility of these in vitro models. Interestingly, no significant In addition, proteomic analysis of a subset of samples was performed which revealed Table S7 ; Fig. 5d ). A total of 36 features including S100P and HIST2H3A (H3.2) overlapped 2 1 between proteomics and transcriptomics, validating the results with a different approach.
Next, we considered which drugs might be able to reverse the differences in gene expression treated with various treatments [31] . Drugs that are negatively associated with the resistance 1 signature could potentially reverse the differences observed. A histone deacetylase (HDAC) 2 inhibitor Trichostatin A had the second lowest score (-0.90) and has previously been shown 3 to re-sensitise tamoxifen-unresponsive ER-negative breast cancer cells in vitro [32] . [34] to determine histone modification enrichment. Two H3 lysine methylation modifications 9 (H3K27me3 and H3K4me1) were enriched significantly (Adjusted p = 0.0003 and p = 0.004, 1 0 respectively) whereas no enrichment for histone acetylation was determined. extended treatment ( Fig. 6a-b ). Significantly lower 5-hmC levels in acquired resistant 1 4 compared to dormant tumours were also observed at early on-treatment ( Fig. 6b ), suggesting 1 5 hypomethylation may be predictive of emergence from dormancy. Understanding the mechanisms underlying the maintenance of and escape from dormancy 1 8 have great importance considering most cancer-related deaths are caused by metastasis rather 1 9 than the primary tumour. In this study, we describe the first sequential patient-matched The most up-regulated gene in resistant tumours S100P, previously shown to be an inducer of 1 9 breast cancer metastasis correlated with decreased survival [41] . Recently, S100P 2 0 hypomethylation in blood was demonstrated to be inversely correlated with tissue S100P 2 1 expression and significantly associated with breast cancer, implicating S100P as a potential 2 2 diagnostic marker [42] . High plasma S100P levels have also been correlated with poor 2 3 prognosis in metastatic breast cancer patients, with levels decreasing following treatment, 2 4 suggesting a role of S100P in dynamic monitoring of response [43] . In the present study, 2 5 1 4 S100P gene expression and protein levels were significantly higher in resistant tumours after 1 long-term treatment, as well as being differentially expressed before treatment supporting its 2 potential role as a therapeutic target [44] and a predictive marker. hypomethylation was the first epigenetic alteration identified in cancer, its molecular process 1 6 and effects are not well understood yet [49] . In addition, 5-hmC levels were shown to 1 7 correlate with differentiation status, with higher levels in more differentiated [29] . In 1 8 addition, alterations in DNA methylation in LTED MCF7 cells have been previously reported 1 9
[50]. Our results provide evidence for loss of global DNA methylation process in resistant 2 0 tumours and strengthen the case to use these models for further study. The global decrease in 2 1 5-mC may account for the observed reduction in 5-hmC levels, since 5-mC is converted to 5-2 2 hmC. On the other hand, at early-on time point, 5-hmC levels were significantly reduced with 2 3 no significant change in 5-mC levels suggesting an independent role of 5-hmC mark.
4
Hypomethylated cancer cells have been suggested to be selected to form tumours with 2 5 1 5 increased malignancy [49] . We suggest that hypomethylation in resistant tumours may reflect 1 dedifferentiation process inducing stem-cell-like cell formation. Determining the time point 2 at which that hypomethylation starts, which would allow intervening before it starts to 3 prevent therapy resistance, needs further investigation.
The main genes significantly enriched for epigenetics-associated pathways in the present 5 study are core histone (H3, H4, H2B) genes. Well-known epigenetics-associated genes such 6 as DNA methyltransferase (DNMT) were not differentially expressed in the present study. 7 Therefore, it might be suggested that observed changes in histone gene levels may simply 8 reflect the high proliferation rate in resistant tumours. Although these histone genes are 9 replication-dependent and their levels increase during DNA replication [51], we suggest that 1 0 elevated levels may also result from disrupted DNA replication and packaging. Deregulation 1 1 of histone H2A and H2B were associated with anthracycline resistance in breast cancer cells epigenetic pathways observed in our study may mediate reactivation of ER signalling in 1 8 resistant tumours, rather than simply mirroring the degree of proliferation.
9
Our results indicate alterations both in DNA methylation, and histone modifications 2 0 suggesting a cooperative interplay between them to mediate acquired resistance. HDAC 2 1 inhibitors, which have been shown to regulate DNA methylation [54] , may be successful 2 2 clinically as second-line drugs alone or in combination following endocrine therapy failure as 2 3 there is growing evidence for their tumour selective action [55, 56] . A time-dependent role 2 4
for HDACs in leukaemia has been shown [57] and may also be critical in determining when The authors declare that they have no potential conflicts of interest. the project and helped to write and edit the manuscript. All authors read and approved the 1 9
final manuscript. 
